Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have b...Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods: A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 ?g/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results: After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63?1.26 to 2.03?1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001). Conclusion: The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.展开更多
目的系统评价芬太尼透皮贴剂或吗啡缓释片治疗国人中重度癌痛的疗效及安全性。方法计算机检索中国期刊全文数据库(CNKI)、中国医院知识总库(CHKD)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、万方数据知识服务平台(WA...目的系统评价芬太尼透皮贴剂或吗啡缓释片治疗国人中重度癌痛的疗效及安全性。方法计算机检索中国期刊全文数据库(CNKI)、中国医院知识总库(CHKD)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、万方数据知识服务平台(WANFANG)等相关随机对照试验(RCT)。各数据库检索时间均从创建至2014年7月。由2名数据员按纳入与排除标准独立筛选试验,并对纳入研究的方法学质量进行评价,提取资料;用Rev Man 5.16统计软件对数据进行Meta分析。结果纳入14项RCT共1 440例患者;芬太尼透皮贴剂对疼痛缓解有效率优于吗啡缓释片[OR=1.18,95%CI(0.84,1.65),P=0.34];芬太尼透皮贴剂对生活质量评分改善优于吗啡缓释片[MD=-1.38,95%CI(0.76,2.00),P<0.05];芬太尼透皮贴剂嗜睡、恶心呕吐、便秘、头晕及尿潴留等不良反应发生率均显著低于吗啡缓释片,仅瘙痒发生率显著高于后者,差异均有统计学意义(P<0.05)。结论芬太尼透皮贴剂在国人中重度癌痛治疗中可有效缓解疼痛,改善生活质量评分,且安全性良好。展开更多
文摘Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods: A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 ?g/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results: After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63?1.26 to 2.03?1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001). Conclusion: The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.
文摘目的系统评价芬太尼透皮贴剂或吗啡缓释片治疗国人中重度癌痛的疗效及安全性。方法计算机检索中国期刊全文数据库(CNKI)、中国医院知识总库(CHKD)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、万方数据知识服务平台(WANFANG)等相关随机对照试验(RCT)。各数据库检索时间均从创建至2014年7月。由2名数据员按纳入与排除标准独立筛选试验,并对纳入研究的方法学质量进行评价,提取资料;用Rev Man 5.16统计软件对数据进行Meta分析。结果纳入14项RCT共1 440例患者;芬太尼透皮贴剂对疼痛缓解有效率优于吗啡缓释片[OR=1.18,95%CI(0.84,1.65),P=0.34];芬太尼透皮贴剂对生活质量评分改善优于吗啡缓释片[MD=-1.38,95%CI(0.76,2.00),P<0.05];芬太尼透皮贴剂嗜睡、恶心呕吐、便秘、头晕及尿潴留等不良反应发生率均显著低于吗啡缓释片,仅瘙痒发生率显著高于后者,差异均有统计学意义(P<0.05)。结论芬太尼透皮贴剂在国人中重度癌痛治疗中可有效缓解疼痛,改善生活质量评分,且安全性良好。
